A Single Dose, Non-Randomized, Open-Label, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of AZD9977 in Participants With Renal Impairment
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Maximum observed plasma concentration (Cmax)
研究概览
简要总结
This is a single dose, non-randomized, open-label, parallel group study. The study will be conducted in participants with severe renal impairment and compared with matched participants with normal renal function. The duration of the study for an individual participant from Screening to Follow-up will be approximately 5 weeks.
详细描述
The study will have 4 cohorts, consisting of participants with severe renal impairment who are not on dialysis (Cohort 1), moderate renal impairment (Cohort 2), mild renal impairment (Cohort 3) and participants with normal renal function (Cohort 4). Following completion of Cohort 1 and Cohort 4, pharmacokinetics (PK) and safety data will be reviewed and a decision will be made whether to study unmatched participants with moderate and mild renal impairment (Cohorts 2 and 3, respectively).
Participants will be screened up to 21 days before administration of study drug. Eligible participants will be admitted to the clinical unit either on the evening of Day -2 or on the morning of Day -1. Each participant will receive a single oral dose of the study drug under fasted conditions on Day 1. Participants will be required to remain resident in the clinical unit until the morning of Day 3 but, if participants prefer, may also remain resident until all PK and other study procedures are completed on Day 7. This decision to extend residency will be made at the discretion of the principal investigator. If participants do check out on Day 3, participants will then return to the unit, as scheduled, for collection of PK samples and safety assessments, with a final Follow-up Visit on Day 14.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy matched control participants only (Cohort 4):
- •Participants who are overtly healthy.
- •Stable renal function, with eGFR of ≥ 90 mL/min/1.73m^
- •Renally impaired participants only (Cohorts 1-3):
- •Participants who have renal impairment:
- •Cohort 1 participants with severe renal impairment must have an eGFR lesser than 30 mL/min/1.73m^2 not on dialysis
- •Cohort 2 participants with moderate renal impairment must have an eGFR of greater than or equal to 30 to lesser than 60 mL/min/1.73m^2
- •Cohort 3 participants with mild renal impairment must have an eGFR of greater than or equal to 60 to lesser than 90 mL/min/1.73m^
- •All participants (Cohorts 1-4):
- •Body weight of at least 50 kg and BMI within the range greater than or equal to 18 to lesser than or equal to 35 kg/m^
- •Male or female of non-childbearing potential.
- •Male participants should not donate sperm for the duration of the study.
- •Female participants must have a negative pregnancy test at time of study entry.
- •Capable of giving signed informed consent.
排除标准
- •Healthy matched control participants only (Cohort 4):
- •Evidence of clinically significant cardiovascular, hematological, renal, endocrine, pulmonary, gastrointestinal, hepatic, neurologic, psychiatric, inflammatory or allergic disease.
- •Renally impaired participants only (Cohorts 1-3):
- •Renal transplant participants, participants on dialysis and those with a history of acute kidney injury.
- •All participants (Cohorts 1-4):
- •Any positive result on Screening for serum hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus antibody.
- •Known history of drug or alcohol abuse.
- •History of QT prolongation and arrhythmia.
- •Any moderate or potent inhibitors or inducers of CYP3A
- •Participants with a known hypersensitivity to AZD9977 or any of the excipients of the product.
- •For women only - currently pregnant or breast-feeding.
- •A positive local diagnostic test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening, clinical signs and symptoms consistent with COVID-19, or the patient has been previosuly hospitalised with COVID-19 infection.
研究组 & 干预措施
Treatment - AZD9977
There are 4 cohorts in this arm based on renal function (mild, moderate, severe, and normal). Each cohort will have 8 participants.
干预措施: AZD9977 (Drug)
结局指标
主要结局
Maximum observed plasma concentration (Cmax)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Area under the plasma concentration-time curve from time zero to infinity (AUC)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC0-t)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Time to reach maximum observed plasma concentration (tmax)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Half-life associated with terminal slope of a semi-logarithmic concentration time curve (t½λz)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Terminal elimination rate constant (λz)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Apparent total body clearance of drug from plasma after oral administration (CL/F)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Non-renal clearance of drug from plasma after oral administration (CLNR/F)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Apparent volume of distribution during the terminal phase after oral administration (Vz/F)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Cumulative amount of unchanged drug excreted into the urine (Ae)
时间窗: Day 1 to 3 (Pre-dose, 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post-dose)
To assess the PK of AZD9977 following administration of AZD9977
Mean residence time (MRT)
时间窗: Day 1 to 3 (Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 20, 24, 36, and 48 hours post-dose), Day 4 to 7
To assess the PK of AZD9977 following administration of AZD9977
Renal clearance of the drug from plasma (CLR)
时间窗: Day 1 to 3 (Pre-dose, 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post-dose)
To assess the PK of AZD9977 following administration of AZD9977
Fraction of the drug excreted into the urine (fe)
时间窗: Day 1 to 3 (Pre-dose, 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours post-dose)
To assess the PK of AZD9977 following administration of AZD9977
次要结局
- Number of participants with adverse events and serious adverse events(Day -2 to Day 14)
- Estimated Glomerular Filtration Rate (eGFR)(Screening, Day -1, Day 1 to 3 (Pre-dose, 4, 12, 24 , 36, and 48 hours))